10:44 AM EST - IMV Inc. : Provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in patients with relapses, refractory diffuse large B cell lymphoma. IMV Inc.
shares T.IMV are trading down $0.05 at $0.79.
